What kava kava doses do regulators and studies give?
| Source | Strength | Daily figure |
|---|---|---|
| TGA (Australia), 2002 alert1 | Kava-containing medicines: tablets and capsules up to 125 mg kavalactones; tea bags up to 3 g dried rhizome | Not more than 250 mg kavalactones a day, any dosage form |
| NSW Health3 | Capsule formulations 50 to 100 mg, for the majority | Recommended maximum daily dose 250 mg |
| Traditional use, NSW Health3 | Ground or chewed root | 750 to 8,000 mg kavalactones |
| 2020 review, on US dietary supplements4 | Typically one to three capsules a day, for an adult | 60–250 mg kavalactones a day for one or two months |
| Cochrane review, as cited by a review4 | Symptomatic treatment of anxiety | 60–280 mg kavalactones a day |
The TGA's 2002 practitioner alert gives a limit for kava-containing medicines of not more than 250 mg of kavalactones a day in any dosage form, in tablets or capsules of up to 125 mg each,1 while the 16-week phase III trial by Sarris and colleagues (2020) gave 120 mg twice a day to 171 participants with generalised anxiety disorder and found a non-significant difference in anxiety reduction between kava and placebo.2
Strengths and daily limits
The table is set at the top of the page
NSW Health adds that no toxic dose is well established.3 A DailyMed search for kava returned only a veterinary product, not a human label.
Doses used in human trials
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Sarris 2013, aqueous kava5 | Aqueous kava extract, 120/240 mg kavalactones a day depending on response, versus placebo | 75 participants with GAD enrolled, 58 analysed | 6 weeks |
| Sarris 2020, phase III2 | Aqueous kava root extract tablets, 120 mg kavalactones twice a day, versus placebo | 171 participants with GAD | 16 weeks |
| KADSS, Sarris 20096 | Five tablets a day, 250 mg kavalactones a day, placebo-controlled crossover | 60 adults with 1 month or more of elevated generalized anxiety | 3 weeks |
| Sarris 2012, oxazepam crossover7 | One acute dose of 180 mg kavalactones, against oxazepam 30 mg and placebo | Twenty-two moderately anxious adults aged 18 to 65 | Doses 1 week apart |
| NCT02219880, University of Melbourne8 | Planned 240 mg kavalactones a day, from 60 mg tablets, two tablets twice a day, versus placebo | 210 adults with GAD planned, 178 enrolled | 18 weeks planned |
| NCT045651459 | Three 75 mg kava capsules a day versus placebo | 39 adults with GAD enrolled | One week, then 12 weeks of follow-up |
The NCT02219880 registry entry lists the 2020 Sarris paper among its references; the paper reports 16 weeks and 171 participants, the entry 18 weeks, 210 adults planned and 178 enrolled.28 The University of Florida pharmacokinetic study by Kanumuri and colleagues, in ten healthy volunteers aged 18 to 40 (the study admitted adults aged 18 to 50), gave one group a single 225 mg kavalactones dose and the other three times a day (3 × 75 mg) dosing, and observed higher exposure after the single dose and a longer duration of exposure with the three-times-a-day dosing.10
Preparing kava root powder
A 2020 review says the dried root is ground into a powder, mixed with ambient-temperature water or coconut milk and filtered through a cloth into a suspension.4 It gives water as the traditional solvent, with flavokavains A and B about 100 times higher in an ethanolic preparation than in an aqueous one.4
How long kava is used, and what not to mix with it
NCCIH says kava supplements may be helpful for anxiety but may need to be taken for several weeks to produce an effect, and that kava does not appear to be helpful for symptoms of generalized anxiety disorder.11 The Cochrane review says the data from its studies suggest kava is relatively safe for short-term treatment (1 to 24 weeks), although more information is required.12 For US kava dietary supplements, a 2020 review gives a typical adult daily dose of 60–250 mg kavalactones, as one to three capsules, for one or two months, and none of the pages searched states a cycle of weeks on and weeks off.4
NCCIH advises against using kava together with sedative substances such as benzodiazepines or alcohol.11 NSW Health says it may add to the effects of other central nervous system depressants, including alcohol.3 NCCIH reports rare cases of liver injury linked to kava products, some of them serious or even fatal, including cases from kava beverages prepared with water.11
Storage
A 2020 review lists storage conditions among the factors that could contribute to variations in kava composition, and the improper handling and storage of kava materials as one hypothesised cause of the liver cases, none of these proposals validated.4
Frequently asked questions
How does a kava dose in mg become a volume or syringe mark?
What do Milligram users log for kava kava?
Milligram's report has no line for kava kava, so no logged share is given.
- Kava kavaHalf-life, trial results and liver reports.
- SupplementsThe supplement class in the library.
- Units and dosingHow mg, mcg, IU and syringe units relate.
- How to take creatine monohydrateAnother oral supplement guide.
- Cholecalciferol dosageVitamin D3 doses in studies and labels.
- Omega-3 fish oil dosageOmega-3 doses in studies and labels.
References
- TGA. Kava practitioner alert. tga.gov.au
- The Australian and New Zealand journal of psychiatry (PubMed abstract). Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. 2020. pubmed.ncbi.nlm.nih.gov
- NSW Health. Kava clinical factsheet. health.nsw.gov.au
- Journal article. Kava as a Clinical Nutrient: Promises and Challenges. 2020. pmc.ncbi.nlm.nih.gov
- Journal of clinical psychopharmacology (PubMed abstract). Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. 2013. pubmed.ncbi.nlm.nih.gov
- Psychopharmacology (PubMed abstract). The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. 2009. pubmed.ncbi.nlm.nih.gov
- Human psychopharmacology (PubMed abstract). The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. 2012. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT02219880: Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial. 2018. clinicaltrials.gov
- ClinicalTrials.gov (US National Library of Medicine). NCT04565145: Biomarker Changes and Anxiolytic Effects-Phase 2. 2024. clinicaltrials.gov
- Journal article. Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers. 2022. pmc.ncbi.nlm.nih.gov
- NCCIH. Kava: Usefulness and Safety. nccih.nih.gov
- Journal article. Kava extract versus placebo for treating anxiety. pmc.ncbi.nlm.nih.gov